Clinical trial

Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study

Name
LINK1
Description
There is no standard of care medication regimen for the management of pain and inflammation post-corneal crosslinking (CXL), although most cornea specialists agree on use of an antibiotic and steroid eye drop in the immediate postoperative period. However, steroid tapering schedule and use of additional topical non-steroidal anti-inflammatory (NSAID) eyedrops vary amongst practitioners. The goal of this study is to compare postoperative pain scores between patients receiving a tapering dose of topical steroids over 1-month post-CXL, versus those receiving an intracanalicular dexamethasone insert.
Trial arms
Trial start
2020-02-12
Estimated PCD
2022-10-24
Trial end
2023-04-05
Status
Completed
Phase
Early phase I
Treatment
Dextenza
Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain
Arms:
Group A
Other names:
Intracanalicular dexamethasone insert
Prednisolone Acetate
post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
Arms:
Group B
Size
20
Primary endpoint
Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4)
Assessed at 1 day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total)
Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4)
assessed at day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total)
Eligibility criteria
Inclusion Criteria: * Progressive keratoconus with planned corneal cross-linking in one or both eyes * Age 18 years and older * Ability to provide informed consent for procedures * Ability to attend scheduled follow up visits Exclusion Criteria: * Age less than 18 * Pregnancy/currently breast-feeding * Inability to provide informed consent * Documented adverse reaction to steroid (e.g. "steroid responder", allergy, etc) * Punctal stenosis * Previous corneal transplant surgery * Systemic concomitant use of controlled substance for pain management (i.e. oxycodone) * Concurrent use of topical steroid eye drops * Systemic, topical or intravitreal steroid use within 1 month of baseline * Active history of chronic or recurrent inflammatory eye disease in either eye * History of ocular herpetic infection (inclusive of Herpes Simplex 1/2, Varicella Zoster, Epstein Barr, Cytomegalovirus) * History of neurotrophic keratitis, uncontrolled diabetes, or other disease entities that may preclude proper healing
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Two cohorts of patients will be studied (10 patients each group). Cohort A: intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or another class if allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye 4 times daily x 10 days).\n\nCohort B: Patients are placed on standard postoperative regimen of postoperative fluoroquinolone antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye 4 times daily (QID) x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: 4 times daily x1 week, three times daily (TID) x 1 week, twice daily (BID) x 1 week, and once daily (QD) x 1 week).', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 20, 'type': 'ACTUAL'}}
Updated at
2024-01-30

1 organization

2 products

4 indications

Product
Dextenza
Indication
Keratoconus
Indication
Instability